SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Leith, C. P. Articles by Willman, C. L. Search for Related Content PubMed PubMed Citation Articles by Leith, C. P. Articles by Willman, C. L. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study CP Leith, KJ Kopecky, J Godwin, T McConnell, ML Slovak, IM Chen, DR Head, FR Appelbaum and CL Willman Department of Pathology, University of New Mexico School of Medicine, Albuquerque, USA. Compared with younger patients, elderly patients with acute myeloid leukemia (AML) respond poorly to conventional chemotherapy. To determine if this poor response is due to differences in the biologic characteristics of AML in the elderly, we studied 211 patients (161 de novo, 50 secondary AML) over 55 years of age (median, 68 years) registered to a single clinical trial for previously untreated AML (SWOG 9031, Phase III randomized trial of standard dose cytosine arabinoside and daunomycin + rhG-CSF). Pretreatment leukemic blasts were karyotyped and were also analyzed for intrinsic drug resistance by quantitating expression of the multidrug resistance glycoprotein MDR1 and functional drug efflux using sensitive flow cytometric techniques. Results were correlated with clinical variables and outcome. These elderly AML patients had a high frequency of unfavorable cytogenetics (32%), MDR1 protein expression (71%), and functional drug efflux (58%); each of these factors occurred at high frequencies in both de novo and secondary AML patients and was associated with a significantly poorer complete remission (CR) rate. In multivariate analysis, secondary AML (P = .0035), unfavorable cytogenetics (P = .0031), and MDR1 (P = .0041) were each significantly and independently associated with lower CR rates. Resistant disease was associated with unfavorable cytogenetics (P = .017) and MDR1 expression (P = .0007). Strikingly, elderly MDR1(-) de novo AML patients with favorable/intermediate cytogenetics had a CR rate of 81%; with increasing MDR1 expression, CR rate decreased in this cytogenetic group. MDR1(+) secondary AML patients with unfavorable cytogenetics had a CR rate of only 12%. Thus, AML in the elderly is associated with an increased frequency of unfavorable cytogenetics and MDR1 expression, both of which independently contribute to poor outcomes. The high frequencies of these features in both de novo and secondary elderly AML patients suggest a common biologic mechanism for these leukemias distinct from that in younger patients. Investigation of biologic parameters at diagnosis in AML in the elderly may help identify patients with a high likelihood of achieving CR with conventional regimens, as well as those who may require alternate regimens designed to overcome therapy resistance. Volume 89, Issue 9, pp. 3323-3329, 05/01/1997 Copyright © 1997 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. PRENKERT, B. UGGLA, E. TINA, U. TIDEFELT, and H. STRID Rapid Induction of P-Glycoprotein mRNA and Protein Expression by Cytarabine in HL-60 Cells Anticancer Res, October 1, 2009; 29(10): 4071 - 4076. [Abstract] [Full Text] [PDF] H. J. M. de Jonge, E. S. J. M. de Bont, P. J. M. Valk, J. J. Schuringa, M. Kies, C. M. Woolthuis, R. Delwel, N. J. G. M. Veeger, E. Vellenga, B. Lowenberg, et al. AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance Blood, October 1, 2009; 114(14): 2869 - 2877. [Abstract] [Full Text] [PDF] J.-L. Harousseau, G. Martinelli, W. W. Jedrzejczak, J. M. Brandwein, D. Bordessoule, T. Masszi, G. J. Ossenkoppele, J. A. Alexeeva, G. Beutel, J. Maertens, et al. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older Blood, August 6, 2009; 114(6): 1166 - 1173. [Abstract] [Full Text] [PDF] A. R. Derolf, S. Y. Kristinsson, T. M.-L. Andersson, O. Landgren, P. W. Dickman, and M. Bjorkholm Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005 Blood, April 16, 2009; 113(16): 3666 - 3672. [Abstract] [Full Text] [PDF] H. D. Klepin and L. Balducci Acute Myelogenous Leukemia in Older Adults Oncologist, March 1, 2009; 14(3): 222 - 232. [Abstract] [Full Text] [PDF] P. S. Becker, K. J. Kopecky, A. N. Wilks, S. Chien, J. M. Harlan, C. L. Willman, S. H. Petersdorf, D. L. Stirewalt, T. Papayannopoulou, and F. R. Appelbaum Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia Blood, January 22, 2009; 113(4): 866 - 874. [Abstract] [Full Text] [PDF] T. Buchner, W. E. Berdel, C. Haferlach, T. Haferlach, S. Schnittger, C. Muller-Tidow, J. Braess, K. Spiekermann, J. Kienast, P. Staib, et al. Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group J. Clin. Oncol., January 1, 2009; 27(1): 61 - 69. [Abstract] [Full Text] [PDF] B. D. Shah and J. E. Lancet Frontline Treatment of Acute Myeloid Leukemia: Are We Making Progress? ASCO Educational Book, January 1, 2009; 2009(1): 372 - 377. [Abstract] [Full Text] [PDF] J. Laubach and A. V. Rao Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly Oncologist, October 1, 2008; 13(10): 1097 - 1108. [Abstract] [Full Text] [PDF] C. Langer, M. D. Radmacher, A. S. Ruppert, S. P. Whitman, P. Paschka, K. Mrozek, C. D. Baldus, T. Vukosavljevic, C.-G. Liu, M. E. Ross, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study Blood, June 1, 2008; 111(11): 5371 - 5379. [Abstract] [Full Text] [PDF] E. Walsby, V. Walsh, C. Pepper, A. Burnett, and K. Mills Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts Haematologica, May 1, 2008; 93(5): 662 - 669. [Abstract] [Full Text] [PDF] L. Fianchi, L. Pagano, F. Leoni, S. Storti, M. T. Voso, C. G. Valentini, S. Rutella, A. Scardocci, M. Caira, G. Gianfaldoni, et al. Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia Ann. Onc., January 1, 2008; 19(1): 128 - 134. [Abstract] [Full Text] [PDF] M. R. Baer, H. D. Klepin, and A. S. Artz Acute Leukemia in Older Adults: Are We Treating Too Much or Too Little? ASCO Educational Book, January 1, 2008; 2008(1): 216 - 223. [Abstract] [Full Text] [PDF] M. L. Sorror, B. M. Sandmaier, B. E. Storer, M. B. Maris, F. Baron, D. G. Maloney, B. L. Scott, H. J. Deeg, F. R. Appelbaum, and R. Storb Comorbidity and Disease Status Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation J. Clin. Oncol., September 20, 2007; 25(27): 4246 - 4254. [Abstract] [Full Text] [PDF] R. B. Walter, T. A. Gooley, V. H. J. van der Velden, M. R. Loken, J. J. M. van Dongen, D. A. Flowers, I. D. Bernstein, and F. R. Appelbaum CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy Blood, May 15, 2007; 109(10): 4168 - 4170. [Abstract] [Full Text] [PDF] E. Estey Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients J. Clin. Oncol., May 10, 2007; 25(14): 1908 - 1915. [Abstract] [Full Text] [PDF] N. Kuptsova, K. J. Kopecky, J. Godwin, J. Anderson, A. Hoque, C. L. Willman, M. L. Slovak, and C. B. Ambrosone Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials Blood, May 1, 2007; 109(9): 3936 - 3944. [Abstract] [Full Text] [PDF] X. Thomas, S. Suciu, B. Rio, G. Leone, G. Broccia, G. Fillet, U. Jehn, W. Feremans, G. Meloni, M. Vignetti, et al. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61 70 years: results of the prospective EORTC GIMEMA AML 13 study Haematologica, March 1, 2007; 92(3): 389 - 396. [Abstract] [Full Text] [PDF] S. Meshinchi and R. J. Arceci Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia Oncologist, March 1, 2007; 12(3): 341 - 355. [Abstract] [Full Text] [PDF] F. R. Appelbaum, D. Rosenblum, R. J. Arceci, W. L. Carroll, P. P. Breitfeld, S. J. Forman, R. A. Larson, S. J. Lee, S. B. Murphy, S. O'Brien, et al. End points to establish the efficacy of new agents in the treatment of acute leukemia Blood, March 1, 2007; 109(5): 1810 - 1816. [Abstract] [Full Text] [PDF] J. E. Lancet, I. Gojo, J. Gotlib, E. J. Feldman, J. Greer, J. L. Liesveld, L. M. Bruzek, L. Morris, Y. Park, A. A. Adjei, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia Blood, February 15, 2007; 109(4): 1387 - 1394. [Abstract] [Full Text] [PDF] H. P. Erba Prognostic Factors in Elderly Patients with AML and the Implications for Treatment Hematology, January 1, 2007; 2007(1): 420 - 428. [Abstract] [Full Text] [PDF] C. Marzac, I. Teyssandier, O. Calendini, J.-Y. Perrot, A.-M. Faussat, R. Tang, N. Casadevall, J.-P. Marie, and O. Legrand Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality in 171 Patients with Acute Myeloid Leukemia Clin. Cancer Res., December 1, 2006; 12(23): 7018 - 7024. [Abstract] [Full Text] [PDF] S. Frohling, R. F. Schlenk, S. Kayser, M. Morhardt, A. Benner, K. Dohner, H. Dohner, and for the German-Austrian AML Study Group Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B Blood, November 15, 2006; 108(10): 3280 - 3288. [Abstract] [Full Text] [PDF] S. S. Farag, K. J. Archer, K. Mrozek, A. S. Ruppert, A. J. Carroll, J. W. Vardiman, M. J. Pettenati, M. R. Baer, M. B. Qumsiyeh, P. R. Koduru, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461 Blood, July 1, 2006; 108(1): 63 - 73. [Abstract] [Full Text] [PDF] F. R. Appelbaum, H. Gundacker, D. R. Head, M. L. Slovak, C. L. Willman, J. E. Godwin, J. E. Anderson, and S. H. Petersdorf Age and acute myeloid leukemia Blood, May 1, 2006; 107(9): 3481 - 3485. [Abstract] [Full Text] [PDF] D. Becton, G. V. Dahl, Y. Ravindranath, M. N. Chang, F. G. Behm, S. C. Raimondi, D. R. Head, K. C. Stine, N. J. Lacayo, B. I. Sikic, et al. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421 Blood, February 15, 2006; 107(4): 1315 - 1324. [Abstract] [Full Text] [PDF] R. Latagliata, V. Bongarzoni, I. Carmosino, A. Mengarelli, M. Breccia, P. A. Borza, M. D'Andrea, G. M. D'Elia, S. Mecarocci, S. G. Morano, et al. Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon Ann. Onc., February 1, 2006; 17(2): 281 - 285. [Abstract] [Full Text] [PDF] E. J. Jabbour, E. Estey, and H. M. Kantarjian Adult Acute Myeloid Leukemia Mayo Clin. Proc., February 1, 2006; 81(2): 247 - 260. [Abstract] [Full Text] [PDF] U. Hegenbart, D. Niederwieser, B. M. Sandmaier, M. B. Maris, J. A. Shizuru, H. Greinix, C. Cordonnier, B. Rio, A. Gratwohl, T. Lange, et al. Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors J. Clin. Oncol., January 20, 2006; 24(3): 444 - 453. [Abstract] [Full Text] [PDF] P. A. Mehta, T. A. Alonzo, R. B. Gerbing, J. S. Elliott, T. A. Wilke, R. J. Kennedy, J. A. Ross, J. P. Perentesis, B. J. Lange, and S. M. Davies XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report Blood, January 1, 2006; 107(1): 39 - 45. [Abstract] [Full Text] [PDF] S. Tauro, C. Craddock, K. Peggs, G. Begum, P. Mahendra, G. Cook, J. Marsh, D. Milligan, A. Goldstone, A. Hunter, et al. Allogeneic Stem-Cell Transplantation Using a Reduced-Intensity Conditioning Regimen Has the Capacity to Produce Durable Remissions and Long-Term Disease-Free Survival in Patients With High-Risk Acute Myeloid Leukemia and Myelodysplasia J. Clin. Oncol., December 20, 2005; 23(36): 9387 - 9393. [Abstract] [Full Text] [PDF] R. B. Walter, J. L. Pirga, M. R. Cronk, S. Mayer, F. R. Appelbaum, and D. E. Banker PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism Blood, November 15, 2005; 106(10): 3584 - 3593. [Abstract] [Full Text] [PDF] Z. Benderra, A. M. Faussat, L. Sayada, J.-Y. Perrot, R. Tang, D. Chaoui, H. Morjani, C. Marzac, J.-P. Marie, and O. Legrand MRP3, BCRP, and P-Glycoprotein Activities are Prognostic Factors in Adult Acute Myeloid Leukemia Clin. Cancer Res., November 1, 2005; 11(21): 7764 - 7772. [Abstract] [Full Text] [PDF] B. van der Holt, B. Lowenberg, A. K. Burnett, W. U. Knauf, J. Shepherd, P. P. Piccaluga, G. J. Ossenkoppele, G. E. G. Verhoef, A. Ferrant, M. Crump, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis Blood, October 15, 2005; 106(8): 2646 - 2654. [Abstract] [Full Text] [PDF] M. S. Tallman, D. G. Gilliland, and J. M. Rowe Drug therapy for acute myeloid leukemia Blood, August 15, 2005; 106(4): 1154 - 1163. [Abstract] [Full Text] [PDF] C.-C. Chen, C.-F. Yang, M.-H. Yang, K.-D. Lee, W.-K. Kwang, J.-Y. You, Y.-B. Yu, C.-H. Ho, C.-H. Tzeng, W.-K. Chau, et al. Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia Ann. Onc., August 1, 2005; 16(8): 1366 - 1373. [Abstract] [Full Text] [PDF] S. Amadori, S. Suciu, U. Jehn, R. Stasi, X. Thomas, J.-P. Marie, P. Muus, F. Lefrere, Z. Berneman, G. Fillet, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study Blood, July 1, 2005; 106(1): 27 - 34. [Abstract] [Full Text] [PDF] M. Qadir, K. L. O'Loughlin, S. M. Fricke, N. A. Williamson, W. R. Greco, H. Minderman, and M. R. Baer Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator Clin. Cancer Res., March 15, 2005; 11(6): 2320 - 2326. [Abstract] [Full Text] [PDF] E. P. Alyea, H. T. Kim, V. Ho, C. Cutler, J. Gribben, D. J. DeAngelo, S. J. Lee, S. Windawi, J. Ritz, R. M. Stone, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age Blood, February 15, 2005; 105(4): 1810 - 1814. [Abstract] [Full Text] [PDF] M. S. Tallman New Strategies for the Treatment of Acute Myeloid Leukemia Including Antibodies and Other Novel Agents Hematology, January 1, 2005; 2005(1): 143 - 150. [Abstract] [Full Text] [PDF] Z. Benderra, A.-M. Faussat, L. Sayada, J.-Y. Perrot, D. Chaoui, J.-P. Marie, and O. Legrand Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias Clin. Cancer Res., December 1, 2004; 10(23): 7896 - 7902. [Abstract] [Full Text] [PDF] J. E. Kolitz, S. L. George, R. K. Dodge, D. D. Hurd, B. L. Powell, S. L. Allen, E. Velez-Garcia, J. O. Moore, T. C. Shea, E. Hoke, et al. Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621 J. Clin. Oncol., November 1, 2004; 22(21): 4290 - 4301. [Abstract] [Full Text] [PDF] D. Mahadevan and A. F. List Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies Blood, October 1, 2004; 104(7): 1940 - 1951. [Abstract] [Full Text] [PDF] H. Kang, M. H. Fisher, D. Xu, Y. J. Miyamoto, A. Marchand, A. Van Aerschot, P. Herdewijn, and R. L. Juliano Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides Nucleic Acids Res., August 17, 2004; 32(14): 4411 - 4419. [Abstract] [Full Text] [PDF] P. Saussoy, J.-L. Vaerman, N. Straetmans, V. Deneys, G. Cornu, A. Ferrant, and D. Latinne Differentiation of Acute Myeloid Leukemia from B- and T-Lineage Acute Lymphoid Leukemias by Real-Time Quantitative Reverse Transcription-PCR of Lineage Marker mRNAs Clin. Chem., July 1, 2004; 50(7): 1165 - 1173. [Abstract] [Full Text] [PDF] R. B. Walter, B. W. Raden, M. R. Cronk, I. D. Bernstein, F. R. Appelbaum, and D. E. Banker The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin Blood, June 1, 2004; 103(11): 4276 - 4284. [Abstract] [Full Text] [PDF] P. L. Greenberg, S. J. Lee, R. Advani, M. S. Tallman, B. I. Sikic, L. Letendre, K. Dugan, B. Lum, D. L. Chin, G. Dewald, et al. Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995) J. Clin. Oncol., March 15, 2004; 22(6): 1078 - 1086. [Abstract] [Full Text] [PDF] A. Argiris, Y. Li, B. A. Murphy, C. J. Langer, and A. A. Forastiere Outcome of Elderly Patients With Recurrent or Metastatic Head and Neck Cancer Treated With Cisplatin-Based Chemotherapy J. Clin. Oncol., January 15, 2004; 22(2): 262 - 268. [Abstract] [Full Text] [PDF] J. M. Rowe, D. Neuberg, W. Friedenberg, J. M. Bennett, E. Paietta, A. Z. Makary, J. L. Liesveld, C. N. Abboud, G. Dewald, F. A. Hayes, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group Blood, January 15, 2004; 103(2): 479 - 485. [Abstract] [Full Text] [PDF] R. M. Stone, M. R. O'Donnell, and M. A. Sekeres Acute Myeloid Leukemia Hematology, January 1, 2004; 2004(1): 98 - 117. [Abstract] [Full Text] [PDF] D. Steinbach, S. Wittig, G. Cario, S. Viehmann, A. Mueller, B. Gruhn, R. Haefer, F. Zintl, and A. Sauerbrey The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype Blood, December 15, 2003; 102(13): 4493 - 4498. [Abstract] [Full Text] [PDF] J. H. Lewis, M. L. Kilgore, D. P. Goldman, E. L. Trimble, R. Kaplan, M. J. Montello, M. G. Housman, and J. J. Escarce Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials J. Clin. Oncol., April 1, 2003; 21(7): 1383 - 1389. [Abstract] [Full Text] [PDF] A. El-Osta, M. Lubbert, P. W. Wijermans, T. Licht, and P. A. Jones On the use of DNA methylation inhibitors and the reversal of transcriptional silencing Blood, February 15, 2003; 101(4): 1656 - 1657. [Full Text] [PDF] M. Itoh, T. Kitano, M. Watanabe, T. Kondo, T. Yabu, Y. Taguchi, K. Iwai, M. Tashima, T. Uchiyama, and T. Okazaki Possible Role of Ceramide as an Indicator of Chemoresistance: Decrease of the Ceramide Content via Activation of Glucosylceramide Synthase and Sphingomyelin Synthase in Chemoresistant Leukemia Clin. Cancer Res., January 1, 2003; 9(1): 415 - 423. [Abstract] [Full Text] [PDF] G. Mufti, A. F. List, S. D. Gore, and A. Y.L. Ho Myelodysplastic Syndrome Hematology, January 1, 2003; 2003(1): 176 - 199. [Abstract] [Full Text] [PDF] J. E. Anderson, K. J. Kopecky, C. L. Willman, D. Head, M. R. O'Donnell, F. W. Luthardt, T. H. Norwood, I-M. Chen, S. P. Balcerzak, D. B. Johnson, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study Blood, December 1, 2002; 100(12): 3869 - 3876. [Abstract] [Full Text] [PDF] R. M. Stone The Difficult Problem of Acute Myeloid Leukemia in the Older Adult CA Cancer J Clin, November 1, 2002; 52(6): 363 - 371. [Abstract] [Full Text] [PDF] J. W. Vardiman, N. L. Harris, and R. D. Brunning The World Health Organization (WHO) classification of the myeloid neoplasms Blood, September 18, 2002; 100(7): 2292 - 2302. [Abstract] [Full Text] [PDF] S. S. Farag, S. L. George, E. J. Lee, M. Baer, R. K. Dodge, B. Becknell, T. Fehniger, L. R. Silverman, J. Crawford, C. D. Bloomfield, et al. Postremission Therapy with Low-dose Interleukin 2 with or without Intermediate Pulse Dose Interleukin 2 Therapy Is Well Tolerated in Elderly Patients with Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 9420 Clin. Cancer Res., September 1, 2002; 8(9): 2812 - 2819. [Abstract] [Full Text] [PDF] A. F. List, K. J. Kopecky, C. L. Willman, D. R. Head, M. L. Slovak, D. Douer, S. R. Dakhil, and F. R. Appelbaum Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase Blood, August 13, 2002; 100(5): 1910 - 1912. [Abstract] [Full Text] [PDF] M. R. Baer, S. L. George, R. K. Dodge, K. L. O'Loughlin, H. Minderman, M. A. Caligiuri, J. Anastasi, B. L. Powell, J. E. Kolitz, C. A. Schiffer, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 Blood, July 30, 2002; 100(4): 1224 - 1232. [Abstract] [Full Text] [PDF] J. Menzin, K. Lang, C. C. Earle, D. Kerney, and R. Mallick The Outcomes and Costs of Acute Myeloid Leukemia Among the Elderly Arch Intern Med, July 22, 2002; 162(14): 1597 - 1603. [Abstract] [Full Text] [PDF] A. Tafuri, C. Gregorj, M. T. Petrucci, M. R. Ricciardi, M. Mancini, G. Cimino, C. Mecucci, A. Tedeschi, G. Fioritoni, F. Ferrara, et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia Blood, July 18, 2002; 100(3): 974 - 981. [Abstract] [Full Text] [PDF] S. R. Wolman, H. Gundacker, F. R. Appelbaum, and M. L. Slovak Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study Blood, June 17, 2002; 100(1): 29 - 35. [Abstract] [Full Text] [PDF] G. Garcia-Manero, C. Bueso-Ramos, J. Daniel, J. Williamson, H. M. Kantarjian, and J.-P. J. Issa DNA Methylation Patterns at Relapse in Adult Acute Lymphocytic Leukemia Clin. Cancer Res., June 1, 2002; 8(6): 1897 - 1903. [Abstract] [Full Text] [PDF] F. J. Giles, A. Keating, A. H. Goldstone, I. Avivi, C. L. Willman, and H. M. Kantarjian Acute Myeloid Leukemia Hematology, January 1, 2002; 2002(1): 73 - 110. [Abstract] [Full Text] A. D. Schimmer, D. W. Hedley, L. Z. Penn, and M. D. Minden Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view Blood, December 15, 2001; 98(13): 3541 - 3553. [Full Text] [PDF] A. F. List, K. J. Kopecky, C. L. Willman, D. R. Head, D. L. Persons, M. L. Slovak, R. Dorr, C. Karanes, H. E. Hynes, J. H. Doroshow, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study Blood, December 1, 2001; 98(12): 3212 - 3220. [Abstract] [Full Text] [PDF] C. M. Galmarini, K. Graham, X. Thomas, F. Calvo, P. Rousselot, A. El Jafaari, E. Cros, J. R. Mackey, and C. Dumontet Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia Blood, September 15, 2001; 98(6): 1922 - 1926. [Abstract] [Full Text] [PDF] A. H. Goldstone, A. K. Burnett, K. Wheatley, A. G. Smith, R. M. Hutchinson, and R. E. Clark Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial Blood, September 1, 2001; 98(5): 1302 - 1311. [Abstract] [Full Text] [PDF] D. Grimwade, H. Walker, G. Harrison, F. Oliver, S. Chatters, C. J. Harrison, K. Wheatley, A. K. Burnett, and A. H. Goldstone The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial Blood, September 1, 2001; 98(5): 1312 - 1320. [Abstract] [Full Text] [PDF] M. L. Linenberger, T. Hong, D. Flowers, E. L. Sievers, T. A. Gooley, J. M. Bennett, M. S. Berger, L. H. Leopold, F. R. Appelbaum, and I. D. Bernstein Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin Blood, August 15, 2001; 98(4): 988 - 994. [Abstract] [Full Text] [PDF] R. M. Stone, D. T. Berg, S. L. George, R. K. Dodge, P. A. Paciucci, P. P. Schulman, E. J. Lee, J. O. Moore, B. L. Powell, M. R. Baer, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine Blood, August 1, 2001; 98(3): 548 - 553. [Abstract] [Full Text] [PDF] M. Pallis, M. Grundy, J. Turzanski, R. Kofler, and N. Russell Mitochondrial membrane sensitivity to depolarization in acute myeloblastic leukemia is associated with spontaneous in vitro apoptosis, wild-type TP53, and vicinal thiol/disulfide status Blood, July 15, 2001; 98(2): 405 - 413. [Abstract] [Full Text] [PDF] E. L. Sievers, R. A. Larson, E. A. Stadtmauer, E. Estey, B. Lowenberg, H. Dombret, C. Karanes, M. Theobald, J. M. Bennett, M. L. Sherman, et al. Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse J. Clin. Oncol., July 1, 2001; 19(13): 3244 - 3254. [Abstract] [Full Text] [PDF] D. L. Stirewalt, K. J. Kopecky, S. Meshinchi, F. R. Appelbaum, M. L. Slovak, C. L. Willman, and J. P. Radich FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia Blood, June 1, 2001; 97(11): 3589 - 3595. [Abstract] [Full Text] [PDF] M. M. van den Heuvel-Eibrink, E. A. C. Wiemer, M. J. de Boevere, B. van der Holt, P. J. M. Vossebeld, R. Pieters, and P. Sonneveld MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia Blood, June 1, 2001; 97(11): 3605 - 3611. [Abstract] [Full Text] [PDF] M. Toyota, K. J. Kopecky, M.-O. Toyota, K.-W. Jair, C. L. Willman, and J.-P. J. Issa Methylation profiling in acute myeloid leukemia Blood, May 1, 2001; 97(9): 2823 - 2829. [Abstract] [Full Text] [PDF] O. Legrand, J.-Y. Perrot, G. Simonin, M. Baudard, and J.-P. Marie JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia Blood, January 15, 2001; 97(2): 502 - 508. [Abstract] [Full Text] [PDF] D. Head Problematic WHO Reclassification of Myelodysplastic Syndromes J. Clin. Oncol., October 19, 2000; 18(19): 3447 - 3452. [Full Text] [PDF] E. H. Estey How I treat older patients with AML Blood, September 1, 2000; 96(5): 1670 - 1673. [Full Text] [PDF] O. Legrand, J.-Y. Perrot, M. Baudard, A. Cordier, R. Lautier, G. Simonin, R. Zittoun, N. Casadevall, and J.-P. Marie The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score Blood, August 1, 2000; 96(3): 870 - 877. [Abstract] [Full Text] [PDF] U. Tidefelt, J. Liliemark, A. Gruber, E. Liliemark, B. Sundman-Engberg, G. Juliusson, L. Stenke, A. Elmhorn-Rosenborg, L. Mollgard, S. Lehman, et al. P-Glycoprotein Inhibitor Valspodar (PSC 833) Increases the Intracellular Concentrations of Daunorubicin In Vivo in Patients With P-Glycoprotein-Positive Acute Myeloid Leukemia J. Clin. Oncol., May 9, 2000; 18(9): 1837 - 1844. [Abstract] [Full Text] [PDF] G. V. Dahl, N. J. Lacayo, N. Brophy, K. Dunussi-Joannopoulos, H. J. Weinstein, M. Chang, B. I. Sikic, and R. J. Arceci Mitoxantrone, Etoposide, and Cyclosporine Therapy in Pediatric Patients With Recurrent or Refractory Acute Myeloid Leukemia J. Clin. Oncol., May 9, 2000; 18(9): 1867 - 1875. [Abstract] [Full Text] [PDF] M. Pallis and N. Russell P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway Blood, May 1, 2000; 95(9): 2897 - 2904. [Abstract] [Full Text] [PDF] E. Hellstrom-Lindberg, C. Willman, A. J. Barrett, and Y. Saunthararajah Achievements in Understanding and Treatment of Myelodysplastic Syndromes Hematology, January 1, 2000; 2000(1): 110 - 132. [Abstract] [Full Text] [PDF] L. F. Hutchins, J. M. Unger, J. J. Crowley, C. A. Coltman, and K. S. Albain Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials N. Engl. J. Med., December 30, 1999; 341(27): 2061 - 2067. [Abstract] [Full Text] [PDF] W. Hiddemann, W. Kern, C. Schoch, C. Fonatsch, A. Heinecke, B. Wormann, and T. Buchner Management of Acute Myeloid Leukemia in Elderly Patients J. Clin. Oncol., November 1, 1999; 17(11): 3569 - 3576. [Abstract] [Full Text] [PDF] B. Lowenberg, J. R. Downing, and A. Burnett Acute Myeloid Leukemia N. Engl. J. Med., September 30, 1999; 341(14): 1051 - 1062. [Full Text] [PDF] E. J. Lee, S. L. George, M. Caligiuri, T. P. Szatrowski, B. L. Powell, S. Lemke, R. K. Dodge, R. Smith, M. Baer, and C. A. Schiffer Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420 J. Clin. Oncol., September 1, 1999; 17(9): 2831 - 2831. [Abstract] [Full Text] [PDF] O. Legrand, G. Simonin, A. Beauchamp-Nicoud, R. Zittoun, and J.-P. Marie Simultaneous Activity of MRP1 and Pgp Is Correlated With In Vitro Resistance to Daunorubicin and With In Vivo Resistance in Adult Acute Myeloid Leukemia Blood, August 1, 1999; 94(3): 1046 - 1056. [Abstract] [Full Text] [PDF] C. P. Leith, K. J. Kopecky, I-M. Chen, L. Eijdems, M. L. Slovak, T. S. McConnell, D. R. Head, J. Weick, M. R. Grever, F. R. Appelbaum, et al. Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study Blood, August 1, 1999; 94(3): 1086 - 1099. [Abstract] [Full Text] [PDF] Y.-M. Zhu, E.P. Das-Gupta, and N.H. Russell Microsatellite Instability and p53 Mutations Are Associated With Abnormal Expression of the MSH2 Gene in Adult Acute Leukemia Blood, July 15, 1999; 94(2): 733 - 740. [Abstract] [Full Text] [PDF] S. M. Kornblau, P. F. Thall, Z. Estrov, M. Walterscheid, S. Patel, A. Theriault, M. J. Keating, H. Kantarjian, E. Estey, and M. Andreeff The Prognostic Impact of BCL2 Protein Expression in Acute Myelogenous Leukemia Varies with Cytogenetics Clin. Cancer Res., July 1, 1999; 5(7): 1758 - 1766. [Abstract] [Full Text] [PDF] C. McCoy, S. B. McGee, and M. M. Cornwell The Wilms' Tumor Suppressor, WT1, Inhibits 12-O-Tetradecanoylphorbol-13-acetate Activation of the Multidrug Resistance-1 Promoter Cell Growth Differ., June 1, 1999; 10(6): 377 - 386. [Abstract] [Full Text] R. Advani, H. I. Saba, M. S. Tallman, J. M. Rowe, P. H. Wiernik, J. Ramek, K. Dugan, B. Lum, J. Villena, E. Davis, et al. Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar) Blood, February 1, 1999; 93(3): 787 - 795. [Abstract] [Full Text] [PDF] P. A. Cassileth, D. P. Harrington, F. R. Appelbaum, H. M. Lazarus, J. M. Rowe, E. Paietta, C. Willman, D. D. Hurd, J. M. Bennett, K. G. Blume, et al. Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission N. Engl. J. Med., December 3, 1998; 339(23): 1649 - 1656. [Abstract] [Full Text] [PDF]

	Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020